Buscar en
Clínica e Investigación en Arteriosclerosis (English Edition)
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis (English Edition) Treatment of a high cardiovascular risk patient with McArdle's disease with ...
Journal Information
Vol. 31. Issue 2.
Pages 89-92 (March - April 2019)
Share
Share
Download PDF
More article options
ePub
Visits
15
Vol. 31. Issue 2.
Pages 89-92 (March - April 2019)
Clinical report
DOI: 10.1016/j.artere.2019.02.004
Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors
Tratamiento de un varón con enfermedad de McArdle y muy alto riesgo cardiovascular con inhibidores de PCSK9
Visits
...
Victoria Marco-Benedía,
Corresponding author
vmarcobenedi@gmail.com

Corresponding author.
, Estíbaliz Jarautaa,b, Sofía Pérez-Calahorraa, Ana M. Beaa, Fernando Civeiraa,b
a Clinical Lipid and Arteriosclerosis Research Unit, Hospital Universitario Miguel Servet, IIS (Instituto de Investigación Sanitaria [Health Research Institute]) Aragón, CIBERCV (Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares [Biomedical Research Centre for Cardiovascular Diseases]), Zaragoza, Spain
b Universidad de Zaragoza, Zaragoza, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Abstract

A 60-year-old male with familial combined hyperlipidemia, ischaemic heart disease and type 2 diabetes. Since childhood, intolerance to intense exercise. The patient was diagnosed of McArdle's disease after an episode of rhabdomyolysis associated with statins as treatment after a myocardial infarction. Since then, he had been treated with diet, fibrates and ezetimibe with good tolerance, despite this, LDL cholesterol (cLDL) remained >180mg/dl. He started to be treated with alirocumab 150mg/sc every 14 days, with excellent clinical response and a decrease in cLDL to 15mg/dl. Our case shows that PCSK9 inhibitors are effective and safe in patients with muscle diseases who have statin contraindication, and they are a good therapeutic tool for these patients.

Keywords:
McArdle's disease
Rhabdomyolysis
Statin intolerance
PCSK9 inhibitors
Resumen

Varón de 60 años con hiperlipidemia familiar combinada, cardiopatía isquémica y diabetes tipo 2. Desde la infancia, intolerancia al esfuerzo intenso. Se le diagnosticó enfermedad de McArdle a raíz de rabdomiólisis asociada a estatinas tras un infarto de miocardio. Desde entonces había seguido tratamiento con dieta, fibratos y ezetimiba con buena tolerancia, pero a pesar de ello las concentraciones de colesterol LDL (cLDL) eran >180mg/dl. Se asoció al tratamiento alirocumab 150mg subcutáneos cada 14 días, con excelente respuesta clínica y descenso de cLDL a 15mg/dl, manteniéndose estable desde entonces. Nuestro caso demuestra que los inhibidores de PCSK9 son eficaces y seguros en pacientes con enfermedades musculares que contraindican las estatinas y que son una alternativa terapéutica ideal para este tipo de pacientes.

Palabras clave:
Enfermedad de McArdle
Rabdomiólisis
Intolerancia a estatinas
Inhibidores de PCSK9

Article

These are the options to access the full texts of the publication Clínica e Investigación en Arteriosclerosis (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Clínica e Investigación en Arteriosclerosis (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos